BETAGEN 16/MG TAB 30/TAB

Indications

Approved Uses

Ménière’s disease/syndrome (symptomatic treatment of vertigo, tinnitus and hearing loss) and symptomatic treatment of vestibular vertigo.

Off-Label Uses

No well-established off-label uses supported by strong guideline evidence; sometimes used empirically for other dizziness syndromes, but evidence is limited.

Dosage & Administration

Dosing by Condition

Ménière's disease / Vestibular Vertigo: Initial dose is 8-16mg three times daily. Maintenance dose is 24-48mg daily in divided doses. The maximum daily dose should not exceed 48mg.

Initial Dose

16mg three times daily

Maintenance Dose

24-48mg daily in 2-3 divided doses

Maximum Dose

48 mg per day.

Children's Dosage

Not recommended for use in children and adolescents below age 18 due to lack of data on safety and efficacy.

Dose Adjustment Notes

No routine dose adjustment is generally required in renal or hepatic impairment, but evidence is limited; use caution/monitor in patients with peptic ulcer disease and in asthma.

How to Take

Oral: swallow the tablet with water; take with or after food to minimize gastrointestinal upset.

Side Effects

Common Side Effects

Nausea, dyspepsia/indigestion, headache; may also cause abdominal pain and bloating.

Side Effect Frequency

Common (≥1/100 to <1/10): headache, nausea, dyspepsia; Not known: hypersensitivity reactions (including rash, pruritus, urticaria/angioedema, anaphylaxis) and other GI complaints (e.g., vomiting, abdominal pain, bloating)

Safety & Warnings

Contraindications

Hypersensitivity to betahistine (or any excipient); pheochromocytoma. (Active peptic ulcer disease is generally a warning/precaution rather than an absolute contraindication.)

Warnings & Precautions

Use with caution in bronchial asthma and in patients with active or history of peptic ulcer disease; monitor for hypersensitivity reactions. (Pheochromocytoma is a contraindication rather than a precaution.)

Age Restriction

Not approved under 18 years.

Drug Interactions

Drug Interactions

MAO inhibitors (including MAO-B inhibitors) may increase betahistine exposure; antihistamines (H1 blockers) may reduce betahistine’s effect. No clinically established interaction with beta-2 agonists (only theoretical).

Interaction Severity

MODERATE: MAO inhibitors (including MAO-B inhibitors) may reduce betahistine metabolism and increase exposure. MINOR/THEORETICAL: H1 antihistamines may antagonize betahistine’s effect.

Food Interaction

Take with food.

Special Populations

Pregnancy

Consult Doctor

Children

Not recommended for use in children and adolescents below age 18 due to lack of data on safety and efficacy.

Elderly

Use with caution, although extensive post-marketing experience suggests no dose adjustment is necessary.

Liver Impairment

No specific dose adjustment recommendation; use caution because formal studies in hepatic impairment are lacking (dose individualization based on tolerability/response).

Storage & Patient Advice

Stopping the Medicine

No taper is required; it can be stopped without withdrawal, but patients should follow the prescriber’s plan (often continued for weeks-months to assess benefit) and seek review if symptoms recur.

Overdose

Symptoms: nausea, vomiting, dyspepsia/abdominal pain, somnolence/drowsiness; at very high/intentional overdoses, convulsions and cardiopulmonary complications have been reported. Management: supportive/symptomatic care; consider activated charcoal if early after ingestion (and airway protected); gastric lavage is rarely needed and only for very recent, potentially severe ingestions per toxicology practice.

Monitoring Requirements

No routine laboratory monitoring; monitor clinically for worsening asthma/bronchospasm and for gastrointestinal symptoms/ulcer recurrence in at-risk patients.

Pharmacology

Mechanism of Action

Histaminergic agent with H1 agonist/partial agonist effects and H3 antagonist effects; increases inner-ear microcirculation and facilitates vestibular compensation, reducing endolymphatic pressure and vertigo symptoms.

Onset of Action

Symptom improvement often begins after ~2 weeks; maximal benefit may require several weeks to a few months of continuous therapy.

Duration of Effect

Not well-defined; clinical benefit is maintained only with regular continuous dosing (symptom control rather than a single-dose sustained effect).

Half-Life

Approximately 3-4 hours (reported for the main metabolite 2‑pyridylacetic acid [2‑PAA])

Bioavailability

Readily and almost completely absorbed after oral administration.

Metabolism

Rapid and extensive first‑pass metabolism to inactive 2‑pyridylacetic acid (2‑PAA), primarily via oxidative deamination (MAO-mediated pathways)

Excretion

Primarily renal excretion as metabolites (mainly 2‑pyridylacetic acid), with the majority of the dose recovered in urine within about 24 hours.

Product Information

Available Dosage Forms

Tablet (16 mg) for this SFDA-registered product BETAGEN.

Composition per Dose

Each tablet: 16mg betahistine dihydrochloride

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Primary Use

For the treatment of Ménière's disease symptoms, including vertigo (dizziness), tinnitus (ringing in the ears), and hearing loss.

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.